# 大法官未發表評論，維持聯邦上訴法院的裁決。

*biotech · news · 2026-05-18 · WDIV ClickOnDetroit*

## Key points

- 最高法院拒絕審理藥廠針對醫療保險藥品價格談判的上訴。
- 最高法院決定後，支持該談判計畫的聯邦上訴法院裁決仍然有效。
- 醫療保險談判計畫已為包括Ozempic、Rybelsus和Wegovy在內的25種藥品訂定價格。
- 擴大該計畫的第三輪將使談判的醫療保險藥品數量增加至40種。
- 若無進一步法院行動，只有國會可能有權終止藥品價格談判計畫。

WASHINGTON – The Supreme Court on Monday rejected appeals from pharmaceutical companies that object to negotiating Medicare drug prices with the federal government. The justices did not comment in leaving in place rulings from the federal appeals court in Philadelphia that dismissed the drug manufacturers' claims. The negotiation program was created as part of the 2022 Inflation Reduction Act, which capped years of debate over whether the federal government should be allowed to haggle directly with pharmaceutical companies over the prices of drugs in Medicare. The law required the government to negotiate prices for certain high-cost drugs in the federal insurance program for older adults on an annual basis, with the first deals going into effect in 2026. Not a single Republican voted for the legislation, which was signed by Democratic President Joe Biden. Republicans have been harshly critical of aspects of the law, and Republican President Donald Trump has rolled back programs favoring alternative energy sources. But the administration has embraced the authority to bring drugmakers to the negotiating table. So far, the government has negotiated prices for 25 prescription drugs covered by Medicare, including the massively popular GLP-1 weight-loss and diabetes drugs, Ozempic, Rybelsus and Wegovy. In January, the Trump administration announced drugs targeted for a third round of the program, which would bring the total number of drugs with lower prices for Medicare enrollees to 40. Pharmaceutical companies have forcefully pushed back on the program, arguing policymakers wanting to lower costs should instead rein in insurers and third-party pharmacy benefit managers. But in the absence of court intervention, stopping the program may require an act of Congress. The statute creating the program doesn’t specify an end date. ___ Swenson reported from New York.

**Companies:** Ozempic, Rybelsus, Wegovy
**Countries:** United States

[Read the full story on WDIV ClickOnDetroit](https://www.clickondetroit.com/business/2026/05/18/supreme-court-rejects-appeals-from-drug-manufacturers-over-medicare-price-negotiations/)

---

Canonical: https://newsio.io/zh-TW/n/1047f848-749e-4f91-80cd-65563729ec7c/2022
Summarized by Newsio from WDIV ClickOnDetroit. https://newsio.io/how-it-works